APRIL 1, 2025

Evolving the Treatment Paradigm in Second-Line Primary Biliary Cholangitis With IQIRVO (elafibranor): A First-in-Class PPAR Agonist

Evolving the Treatment Paradigm In Second-Line Primary Biliary Cholangitis With IQIRVO? (elafibranor): A First-in-Class PPAR Agonist Primary biliary cholangitis (PBC; formerly primary biliary cirrhosis) is a chronic, cholestatic liver dis.ease stemming from autoimmune destruction of small bile ducts.1-3 The pooled global incidence is 14.60 per INDICATION IQIRVO? is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an